clinical trials
-
AstraZeneca’s HICKORY Trial Fails Primary Endpoint Due to Design Mismatch
AstraZeneca’s Phase 3 HICKORY trial for efzimfotase alfa failed its primary endpoint, highlighting critical gaps in rare disease clinical trial feasibility.
-
Green Cross Secures Approval for Advanced Flu Vaccine Clinical Trials
South Korea’s Ministry of Food and Drug Safety has cleared Green Cross to begin Phase 2 and 3 trials for its high-immunogenicity flu vaccine candidate, GC3114B.
-
Medical Breakthroughs Offer New Hope for Pancreatic Cancer Patients
Recent clinical trials for a new vaccine and targeted delivery systems are showing promise in preventing and treating pancreatic cancer.
-
Cancer Research and Advocacy: From Clinical Breakthroughs to Personal Narratives
New colorectal screening guidelines and clinical trial successes highlight cancer progress alongside high-profile disclosures on pediatric treatment.
-
New Baxdrostat Trial Offers Hope for Stubborn High Blood Pressure
A promising new experimental drug, baxdrostat, has demonstrated the ability to lower resistant blood pressure and protect kidney function in recent clinical trials.
-
Deep Learning Tackles Clinical Data Drift and Cancer Prognosis
New research in 2026 demonstrates how deep learning is moving beyond experimental use to stabilize clinical trials and improve cancer diagnostic accuracy.
-
Novo Nordisk Stock Falls on Disappointing CagriSema Trial Results
Novo Nordisk A/S (NVO) shares dropped pre-market after its experimental obesity drug, CagriSema, failed to meet its primary endpoint in a Phase 3 trial, impacting its competitive standing.
-
Vertex Nears Historic Breakthrough: Stem Cell Therapy Poised to Transform Type 1 Diabetes Treatment
Vertex Pharmaceuticals is on the brink of revolutionizing type 1 diabetes care, as its stem cell therapy VX-880 enters final clinical trials. With historic progress in restoring insulin production, the company stands at the forefront of a new era in…
-
Gene Therapy Breakthrough Slows Huntington’s Disease Progression by 75%
A pioneering gene therapy, AMT-130, is the first to significantly slow Huntington’s disease, marking a historic advance for patients and families.
-
Celcuity Stock Skyrockets Following Breakthrough Breast Cancer Drug Trial Results
Celcuity Inc. (NASDAQ: CELC) shares surged over 100% after the company announced breakthrough Phase 3 trial results for its breast cancer drug, gedatolisib. The trial demonstrated unprecedented efficacy in slowing disease progression in advanced breast cancer patients.
-
Wegovy Shows Promise in Treating Advanced Liver Disease, Study Finds
Clinical trials reveal Wegovy’s potential to treat metabolic dysfunction-associated steatohepatitis (MASH), reducing liver inflammation and fibrosis in patients.
-
Daily Peanut Exposure Offers Hope for Adults with Severe Allergies
A groundbreaking study shows that daily peanut exposure can desensitize adults with severe allergies, reducing life-threatening risks.
-
Stem Cell Therapy Shows Promise for Parkinson’s Treatment
Two small studies suggest stem cell transplants may ease Parkinson’s symptoms by restoring dopamine production, offering hope for future treatments.